Choice Institutional Equities raises Yatharth Hospitals target to ₹1,350 on Advent partnership

⚡ Key Financial Takeaways

Choice Institutional Equities revised Yatharth Hospitals' target price from ₹1,100 to ₹1,350, maintaining a 'Buy' rating.

Management reaffirmed confidence in sustaining over 30% organic growth, supported by Advent-led acquisitions.

The company aims to add ₹2,000 million in EBITDA through strategic acquisitions, targeting over 3x business growth in three years.

Analysts estimate the Advent investment will add approximately 1,200 beds by FY29, bringing total capacity to around 6,000 beds.

The valuation is based on a 20x multiple of the average FY28-29E EV/EBITDA, with margins expected to remain stable at approximately 24%.

💡 Why It Matters

The partnership with Advent International signals a significant shift in Yatharth Hospitals' growth model, moving from purely organic expansion to a hybrid model that includes large-scale M&A. For investors, the clarification on capacity expansion (adding ~1,200 beds) and the specific EBITDA target (₹2,000 Mn) provides tangible metrics to track the company's execution over the next three years. The maintenance of margins at ~24% despite rapid scaling is a key indicator of operational efficiency.

Analyst Upgrade Driven by Strategic Partnership

Choice Institutional Equities has upgraded its outlook for Yatharth Hospitals, raising its target price to ₹1,350 from the previous level of ₹1,100. The brokerage maintains a 'Buy' rating on the stock, citing a strategic partnership with global private equity firm Advent International as a key catalyst for the company's next phase of growth.

The revision follows detailed interactions with Yatharth's management, including Director Yatharth Tyagi and Group Chief for Strategy, M&A & IR, Ashutosh Kumar Jha. These discussions focused on the company's capital allocation strategy and its roadmap for mergers and acquisitions (M&A).

Growth Projections and Capacity Expansion

Management reiterated its confidence in sustaining organic growth of over 30%. According to the report, this organic trajectory will be supplemented by incremental revenue and earnings from acquisitions led by Advent. The company has set a specific target to add ₹2,000 million in EBITDA through these strategic moves.

This approach is expected to provide visibility for more than a threefold increase in business size over the next three years. Crucially, management indicated that this expansion will occur while maintaining operating margins at approximately 24%.

In its financial estimates, Choice Institutional Equities has factored in an additional 1,200 beds by FY29, attributed to the Advent investment. This expansion is projected to bring Yatharth's total bed capacity to approximately 6,000 by the end of FY29.

Valuation Methodology

The brokerage's valuation framework remains consistent with its previous assessment, utilizing a 20x multiple on the average Enterprise Value to EBITDA (EV/EBITDA) for fiscal years 2028 and 2029. The primary driver for the higher target price is the inclusion of the projected earnings and revenue uplift from the Advent-led acquisition pipeline, which sits on top of the existing organic growth assumptions.

Disclaimer

The views and investment tips expressed in this report are those of Choice Institutional Equities and not of NEWZA or its management. Investors are advised to consult with certified financial experts before making any investment decisions.

🏛️ Background & Context

Yatharth Hospitals is a multi-specialty healthcare provider. The involvement of Advent International, a major global private equity firm, suggests a long-term capital injection aimed at scaling the hospital chain across India. The target of 6,000 beds by FY29 represents a substantial increase in the company's infrastructure footprint.

👁️ What To Watch Next

Investors should monitor the pace of bed additions to see if the company is on track to reach the 6,000-bed capacity by FY29. Additionally, tracking the realization of the ₹2,000 Mn EBITDA target from acquisitions will be critical to validating the analyst's 3x growth projection. Quarterly earnings reports will be key to assessing whether margins remain stable at the projected ~24% level during this expansion phase.